← All trials
NCT06256445
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 26, 2024
- Primary completion
- Aug 7, 2024
- Completion date
- Aug 1, 2025
- First posted
- Feb 13, 2024
- Last posted
- Mar 29, 2024
- Enrollment
- 252
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AMIpharm Co., Ltd.Lead sponsor
- Chung-Ang UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.